SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Takiyama Y, Oyanagi S, Kawashima S et al. A clinical and pathological study of a large Japanese family with Machado–Joseph disease tightly linked to the DNA markers on chromosome 14Q. Neurology 1994; 44: 13021308.
  • 2
    Trouillias P. L-5-Hydroxytryptophan treatment in hereditary ataxia: clinical and etiological correlations. Mov. Disord. 1990; 5 (Suppl. 1): 6.
  • 3
    Trouillas P, Xie J, Adeleine P et al. Buspirone: a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy. Arch. Neurol. 1997; 54: 749752.
  • 4
    Friedman JH. Machado-Joseph disease/spinocerebellar ataxia 3. Responsive to buspirone. Mov. Disord. 1997; 12: 613614.
  • 5
    Takei A, Honma S, Kawashima A et al. Beneficial effects of tandospirone on ataxia of a patient with Machado–Joseph disease. Psychiatry Clin. Neurosci. 2002; 56: 181185.
  • 6
    Trouillas P, Takayanagi T, Hallet M et al. International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome. J. Neurol. Sci. 1997; 145: 205211.
  • 7
    Zung WWK, Durham NC. A self-rating depression scale. Arch. Gen. Psychiatry 1963; 12: 6370.
  • 8
    Maura G, Reiteri M. Serotonin 5-HT1D and 5-HT1A receptors respectively mediate inhibition of glutamate release and inhibition of cyclic GMP production in rat cerebellum in vitro. J. Neurochem. 1996; 66: 203209.
  • 9
    Corona T, Rivera C, Otero E, Stopp L. A longitudinal study of the effects of an L-dopa drug holiday on the course of Parkinson's disease. Clin. Neuropharmacol. 1995; 18: 325332.
  • 10
    Feldman RG, Kaye JA, Lannon MC. Parkinson's disease: follow-up after ‘drug holiday’. J. Clin. Pharmacol. 1986; 26: 662667.
  • 11
    Martinez F, Castillo J, Castro A, Lema M, Noya M. The results of drug holiday in Parkinson's disease. Neurologia 1992; 7: 254259.
  • 12
    Teychenne PF, Bergsrud D, Elton RL, Racy A. Bromocriptine: long-term low-dose therapy in Parkinson's disease. Clin. Neuropharmacol. 1986; 9: 138145.
  • 13
    Wieland S, Fischette C, Lucki I. et al. Effect of chronic treatments with tandospirone and imprimine on serotonin-mediated behavioral responses and monoamine receptors. Neuropharmacology 1993; 32: 561573.